BioArctic targets fully subcutaneous Leqembi treatment pathway with weekly autoinjector dosing strategy

• BioArctic outlined a plan to support a fully subcutaneous Leqembi treatment pathway, shifting initiation and maintenance toward a weekly 500 mg autoinjector.
• The strategy targets broader access through at-home dosing, reducing reliance on IV infusion capacity across care settings.
• Planning assumes comparable outcomes to IV dosing, supported by bioequivalent exposure at 104% (90% CI: 99.1%-109%).
• Operational approach includes allowing switches between IV and subcutaneous dosing, with missed doses permitted up to six days late.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief on July 12, 2026, and is solely responsible for the information contained therein.